NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.26 -0.02 (-0.88 %) (As of 12/18/2018 04:00 PM ET)Previous Close$2.26Today's Range$2.12 - $2.4252-Week Range$2.12 - $11.93Volume219,300 shsAverage Volume327,771 shsMarket Capitalization$90.68 millionP/E Ratio7.52Dividend YieldN/ABeta1.64 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland. Receive AVDL News and Ratings via Email Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVDL Previous Symbol CUSIPN/A Webwww.avadel.com Phone636-449-1830 Debt Debt-to-Equity Ratio1.74 Current Ratio3.15 Quick Ratio3.02 Price-To-Earnings Trailing P/E Ratio7.52 Forward P/E Ratio-1.13 P/E GrowthN/A Sales & Book Value Annual Sales$172.74 million Price / Sales0.48 Cash Flow$0.4132 per share Price / Cash Flow5.47 Book Value$2.18 per share Price / Book1.04 Profitability EPS (Most Recent Fiscal Year)$0.31 Net Income$68.27 million Net Margins-34.91% Return on Equity-86.08% Return on Assets-23.33% Miscellaneous Employees180 Outstanding Shares37,010,000Market Cap$90.68 million OptionableOptionable Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions What is Avadel Pharmaceuticals' stock symbol? Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL." How will Avadel Pharmaceuticals' stock buyback program work? Avadel Pharmaceuticals declared that its board has initiated a stock buyback plan on Wednesday, March 28th 2018, which authorizes the company to repurchase $7,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 2.7% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its earnings results on Monday, November, 5th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.10. The company earned $19.83 million during the quarter, compared to analysts' expectations of $20.11 million. Avadel Pharmaceuticals had a negative net margin of 34.91% and a negative return on equity of 86.08%. View Avadel Pharmaceuticals' Earnings History. When is Avadel Pharmaceuticals' next earnings date? Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Avadel Pharmaceuticals. What guidance has Avadel Pharmaceuticals issued on next quarter's earnings? Avadel Pharmaceuticals updated its FY 2018 earnings guidance on Monday, November, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90-105 million, compared to the consensus revenue estimate of $102.69 million. What price target have analysts set for AVDL? 5 analysts have issued 12 month price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $14.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $10.00 in the next year. This suggests a possible upside of 342.5% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals. What is the consensus analysts' recommendation for Avadel Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Avadel Pharmaceuticals. Has Avadel Pharmaceuticals been receiving favorable news coverage? News coverage about AVDL stock has trended somewhat positive on Tuesday, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. Who are some of Avadel Pharmaceuticals' key competitors? Some companies that are related to Avadel Pharmaceuticals include Evelo Biosciences (EVLO), Clementia Pharmaceuticals (CMTA), Abeona Therapeutics (ABEO), ArQule (ARQL), resTORbio (TORC), Evolus (EOLS), Keryx Biopharmaceuticals (KERX), American Brivision (Holding) (ABVC), Five Prime Therapeutics (FPRX), OptiNose (OPTN), Stemline Therapeutics (STML), Concert Pharmaceuticals (CNCE), Marker Therapeutics (MRKR), Minerva Neurosciences (NERV) and Aclaris Therapeutics (ACRS). Who are Avadel Pharmaceuticals' key executives? Avadel Pharmaceuticals' management team includes the folowing people: Mr. Michael S. Anderson, CEO & Director (Age 69)Mr. Michael F. Kanan, Sr. VP & CFO (Age 55)Mr. Gregory J. Divis, Exec. VP & COO (Age 53)Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)Dr. David Monteith, VP of R&D (Age 54) Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (17.23%), Acadian Asset Management LLC (3.05%), Morgan Stanley (2.11%), Renaissance Technologies LLC (1.58%), Janney Montgomery Scott LLC (0.62%) and Alps Advisors Inc. (0.19%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, James E Flynn, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals. Which major investors are selling Avadel Pharmaceuticals stock? AVDL stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC and GSA Capital Partners LLP. Company insiders that have sold Avadel Pharmaceuticals company stock in the last year include James E Flynn, Michael S Anderson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals. Which major investors are buying Avadel Pharmaceuticals stock? AVDL stock was bought by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, Morgan Stanley, Janney Montgomery Scott LLC and Alps Advisors Inc.. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Avadel Pharmaceuticals' stock price today? One share of AVDL stock can currently be purchased for approximately $2.26. How big of a company is Avadel Pharmaceuticals? Avadel Pharmaceuticals has a market capitalization of $90.68 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe. What is Avadel Pharmaceuticals' official website? The official website for Avadel Pharmaceuticals is http://www.avadel.com. How can I contact Avadel Pharmaceuticals? Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected] MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 211 (Vote Outperform)Underperform Votes: 186 (Vote Underperform)Total Votes: 397MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: What are earnings reports?